Kolltan Approaching First IND Submission For RTK-Targeted Oncology Drug Candidate

22 Feb 2013

Having raised about $75 million in venture funding since its 2007 inception, Kolltan Pharmaceuticals is getting closer to the clinic with novel oncology candidates targeting receptor tyrosine kinases.

Some new biopharma companies move remarkably fast in bringing drug candidates into the clinic and even to market. This is not such a case, however. After more than five years and a venture capital top-up to a total of $75 million last year, Kolltan Pharmaceuticals Inc. hopes to bring a lead monoclonal antibody for cancer to the IND-submission stage before the end of 2013.

The biotech works in areas similar to Pfizer Inc.’s renal cell carcinoma and gastrointestinal cancer drug Sutent (sunitinib), which...